# Repurposed Drug Intelligence Hub

**Goal:** give patients, caregivers, and clinicians a fact-checked launchpad for non-traditional / off-label cancer discussions. Every entry links to primary sources, highlights real trials, and flags risks. Use this to talk with your oncology team‚Äînot as DIY dosing instructions.

> ‚ö†Ô∏è **Safety first:** preclinical ‚â† clinical. Never self-dose veterinary or black-market drugs. Discuss prescriptions, trials, and interactions with licensed oncologists. This page does **not** provide dosing directions.

---

## üö´ Why not ‚Äúalternative-only‚Äù cancer treatment?

- [NCI Cancer Currents](https://www.cancer.gov/news-events/cancer-currents-blog/2017/alternative-medicine-cancer-survival): patients choosing alternative medicine instead of conventional therapy had substantially worse survival in observational analyses.
- [JAMA Oncology (Johnson et al.)](https://pubmed.ncbi.nlm.nih.gov/30027204/): complementary-medicine users were more likely to refuse standard therapy, leading to higher mortality.

Use repurposed drugs **with** oncologist-approved care (clinical trials, adjunctive discussions), not as replacements.

## üß† Master repurposing databases

| Resource | Why it matters |
|----------|----------------|
| [ReDO Project ‚Äì PubMed overview](https://pubmed.ncbi.nlm.nih.gov/30679953/) | Peer-reviewed description of the Repurposing Drugs in Oncology (ReDO) effort and database criteria. |
| [ReDO Project ‚Äì full text](https://pmc.ncbi.nlm.nih.gov/articles/PMC6345075/) | Open version for agents/analysts to parse the entire dataset. |
| [ReDO Project official site](https://www.redo-project.org/) | Live catalog of non-cancer drugs with anticancer evidence; jump-off point for deeper research. |
| [Drug repurposing trial landscape (Frontiers 2021)](https://www.frontiersin.org/articles/10.3389/fphar.2021.790952/full) | Maps global repurposing trials and methodology‚Äîgreat for building the full list beyond the examples below. |

**Agent instructions:** for each candidate drug capture mechanism, evidence tier, best human trial, negative results, safety/regulatory notes, and clinical status. Cite every claim.

---

## ü¶† Ivermectin (still investigational for cancer)

- **Mechanistic reviews:** [2018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/), [2020/2021](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/), [2024](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11008553/), [2025](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12566834/) ‚Äî all highlight mostly cell-line/animal data and the absence of solid human efficacy.
- **Clinical trial:** [NCI-2022-02421](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-02421) testing ivermectin + pembrolizumab in metastatic triple-negative breast cancer (phase I dose-finding/early signal). For context, pembrolizumab + chemo already improves PD-L1‚Äìpositive TNBC survival per [KEYNOTE-355](https://www.cancer.gov/news-events/cancer-currents-blog/2022/pembrolizumab-triple-negative-breast-cancer-improves-survival).
- **Safety/regulatory:** [FDA consumer warning](https://www.fda.gov/consumers/consumer-updates/ivermectin-and-covid-19) and [Stromectol label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s024s025lbl.pdf) emphasize prescription-only use and documented toxicities.

_Remember: discuss only via legitimate medical channels or clinical trials._

---

## ‚öñÔ∏è Aspirin in colorectal cancer

| Evidence | Takeaway |
|----------|----------|
| [ALASCCA NEJM 2025](https://www.nejm.org/doi/full/10.1056/NEJMoa2504650) + [ESMO summary](https://www.esmo.org/oncology-news/low-dose-adjuvant-aspirin-decreases-incidence-of-recurrence-among-patients-with-resected-pi3k-altered-crc) + [ASCO Post](https://ascopost.com/news/september-2025/localized-pi3k-altered-colorectal-cancer-does-low-dose-aspirin-reduce-the-risk-of-recurrence/) | Low-dose aspirin reduced recurrence **only** in PI3K-altered resected CRC; precision-medicine signal. |
| [ASCOLT trial (PubMed 39824200)](https://pubmed.ncbi.nlm.nih.gov/39824200/) | Broad CRC population did **not** see significant DFS benefit. |

Interpretation: aspirin may help specific molecular subgroups, not everyone.

---

## üíä Metformin in breast cancer

- [MA.32 randomized trial (ASCO JCO)](https://ascopubs.org/doi/10.1200/JCO.23.00296) ‚Äî metformin did **not** improve invasive disease-free or overall survival in the adjuvant setting. Observational hype did not translate in a large RCT.

---

## üß™ Disulfiram + copper in glioblastoma

- [JAMA Network Open RCT](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802966): adding disulfiram + copper to alkylating chemotherapy for recurrent GBM failed to improve 6‚Äëmonth survival and increased grade ‚â•3 toxicities.

Lesson: not all repurposing ideas work‚Äîeven after earlier enthusiasm.

---

## üìç Hydroxychloroquine in pancreatic cancer

- [Randomized phase II (PMC8086597)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086597/) combined HCQ with gemcitabine/nab-paclitaxel preoperatively to target autophagy.
- [ClinicalTrials.gov NCT01273805](https://clinicaltrials.gov/study/NCT01273805) lists additional HCQ studies.

Still experimental; watch for results before considering outside trials.

---

## üß¨ Mebendazole in brain tumors

- [Phase 1 trial NCT01729260](https://clinicaltrials.gov/study/NCT01729260) + [high-dose clinical report](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817892/) show feasibility with temozolomide.
- [AACR brain penetration study](https://aacrjournals.org/clincancerres/article/21/15/3462/78928) explains the pharmacology that justified human testing.

---

## üíâ Propranolol in angiosarcoma

- Case reports: [propranolol + metronomic chemo](https://ecancer.org/en/journal/article/499-targeted-therapy-with-propranolol-and-metronomic-chemotherapy-combination-sustained-complete-response-of-a-relapsing-metastatic-angiosarcoma) and [propranolol + cyclophosphamide](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161779/).
- Trial: [NCT04518124](https://clinicaltrials.gov/study/NCT04518124) ‚Äúwindow-of-opportunity‚Äù propranolol monotherapy in cutaneous angiosarcoma.
- Overview: [Anticancer Fund explainer](https://www.anticancerfund.org/en/news/exploring-beta-blocker-propranolol-angiosarcoma-treatment).

Rare cancer but credible signal ‚Üí ongoing research.

---

## üçÑ Itraconazole (antifungal) in oncology

- [Mechanistic review](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529765/).
- Clinical work: [NSCLC pharmacodynamics trial NCT02357836](https://clinicaltrials.gov/study/NCT02357836) and [window-of-opportunity study (PubMed 32847935)](https://pubmed.ncbi.nlm.nih.gov/32847935/).
- [ReDO itraconazole overview](https://ecancer.org/en/journal/article/521-repurposing-drugs-in-oncology-redo-itraconazole-as-an-anti-cancer-agent).

---

## üß¨ Doxycycline & cancer stem cells

- [Preclinical CSC study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405729/) showed doxycycline affecting cancer stem-like cells.
- [Frontiers clinical study](https://www.frontiersin.org/articles/10.3389/fonc.2018.00452/full) and [trial NCT02775695](https://clinicaltrials.gov/study/NCT02775695) explore translation.

---

## üß™ Cimetidine in colorectal cancer

- [Perioperative RCT (PubMed 10223557)](https://pubmed.ncbi.nlm.nih.gov/10223557/) hinted at survival impact when given around surgery.
- [ReDO cimetidine review](https://ecancer.org/en/journal/article/485-repurposing-drugs-in-oncology-redo-cimetidine-as-an-anti-cancer-agent) compiles the mixed evidence.

---

## üåç Global trial + evidence search tools

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [NIH PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [PubMed Central (full text)](https://www.ncbi.nlm.nih.gov/pmc/)
- [FDA Drug Database](https://www.accessdata.fda.gov/scripts/cder/daf/)

Use these to validate claims, monitor recruiting trials, and gather authoritative references for clinicians.
